Non-small cell lung cancer

Indexed in Crossref

184 abstracts matching non-small cell lung cancer from the meeting's journal supplement, fetched live from Crossref 2026-11-12 09:29 UTC. This is a keyword search, not the complete abstract book.

• E20592
  Inpatient chemotherapy in lung cancer: Survival outcomes in small cell and non–small cell lung cancer.

  Esteban Toro Velez, Carolina Velez-Mejia, Andrew Stewart Poklepovic, Renato G. Martins
• E20777
  Double lung transplantation in patients with metastatic lung-limited non–small cell lung carcinoma (NSCLC): A case series.

  Young Kwang Chae, Liam Chung, Ronald Seungjune Min, Sang Hwa Kim et al.
• 8625
  Osimertinib combined with bevacizumab and chemotherapy as 1L treatment in EGFR-mutated metastatic non-squamous non-small cell lung cancer (nsq NSCLC) with concurrent mutations.

  Liang Liu, Yanjuan Xiong, Yang Wang, Shengguang Wang et al.
• 8658
  Genomic clonality analysis of patients with metastatic lung-limited non–small cell lung carcinoma (NSCLC) who underwent double lung transplantation (DLT) across timepoints and tumor region.

  Sang Hwa Kim, Young Kwang Chae, Liam Il-Young Chung, Ronald Seungjune Min et al.
• 10550
  Contemporary trends in early-stage non–small cell lung cancer diagnosis and disparities, 2018–2022.

  Ahmed Minhas
• E20658
  Association between metastatic site and survival in non–small cell lung cancer: A SEER-based cohort study.

  Kun Yang
• E13743
  Patient access to precision medicine: Immune checkpoint inhibitor (ICI) usage in non-small cell lung cancer (NSCLC) and association with income levels across multiple Asian markets.

  Pieter De Richter, Mei Yee Koo, Laylian Chew
• E24006
  Arrhythmic outcomes following immune checkpoint inhibitor (ICI) therapy in patients with non–small cell lung cancer (NSCLC) without heart failure or myocarditis.

  Phuuwadith Wattanachayakul, Thitiphan Srikulmontri, Elvis Obomanu, Riley Marotta et al.
• 8589
  Response to cancer immunotherapy for p53 antibody-positive non-small cell lung cancer according to treatment regimen.

  Tetsuo Shimizu, Yoshiko Nakagawa
• E20096
  Impact of reflexive next-generation sequencing on treatment initiation in non–small cell lung cancer.

  Sydney Denney, Sahar Forootan Sedigh, Katharine Thomas
• E15009
  Cerebrospinal fluid proteomics to identify biomarkers for the diagnosis and prediction of leptomeningeal metastasis from non–small cell lung cancer.

  Zhimin Zeng
• 8562
  Impact of immunotherapy era on survival in stage IV non–small cell lung cancer.

  Tahreem Malik, Thomas Greco, Joseph Maslak
• 8042
  Fraction genome altered to predict survival in early-stage non–small cell lung cancer.

  Mobina Shrestha, Salina Dahal, Vishal Mandal
• E20591
  First-line real-world outcomes of atezolizumab- and pembrolizumab-based regimens in non-squamous non–small-cell lung cancer.

  Sevindzh Evdokimova, Anna Kornietskaya, Larisa Bolotina, Alexander Alexandrovich Fedenko et al.
• E20755
  Clinical characteristics and prognostic analysis of epidermal growth factor receptor–mutated non–small cell lung cancer patients with malignant pleural effusion.

  Yu Houjian
• E20711
  Targeting MAT2A-mediated metabolic pathways: A novel strategy for non-small cell lung cancer therapy.

  Qiyu Fang, Qian Liu, Yimin Chen, Shengxiang Ren
• E20513
  Effects of RPL37 on the proliferation, migration, and invasion of non–small cell lung cancer cells.

  Ya-Wen Luo, Dan Zang, Jun Chen
• 8068
  Immune aging within the tumor microenvironment as a predictor of survival in non–small cell lung cancer.

  Taeyun Kim, Seokho Yang
• 8543
  Smoking–genomic discordance in metastatic non–small cell lung cancer.

  Ilit Turgeman, Federica Pecci, Yakatherina Shulman, Kirill Drozdov et al.
• E14586
  The role of rhamnose derived from gut microbiome in modulating the efficacy of non-small cell lung cancer immunotherapy.

  Xu Han, Jun Chen
• E20558
  Distinct clinical and genomic landscape of bilateral parenchymal non–small cell lung cancer (NSCLC) using the AACR GENIE BPC database.

  Jongwoo Kim, Seoin Kim, João Pedro Thimotheo Batista, Donghoon Shin et al.
• E23020
  Use of duration of response as an interpretable endpoint in non-small cell lung cancer drug approvals.

  Brittany Avin McKelvey, Tod Guidry, Andrea Ferris
• 8066
  Stage-dependent divergence of immune prognostic signatures in non–small cell lung cancer.

  Praveen Thapa, Trilok Shrivastava, Ashish Nepal, Anupam Raj Upadhyay
• 8045
  Non-surgical management and outcome of 1,113 patients with stage I-II non-small cell lung cancer (NSCLC) in a 20-year cohort.

  Ping Yang, Cristina Ou, Vinicius Ernani, Jason A. Wampfler et al.
• E23357
  Comparing line of therapy selection methods in advanced non–small cell lung cancer (aNSCLC): A simulation study.

  Shivani Aggarwal, Neisha Opper, Hoa Van Le
• E20574
  Clinical and translational study of YBX1 as a biomarker and therapeutic target in bone metastasis of non–small cell lung cancer.

  Yongsheng Wang, Liyun Miao
• E20727
  Zongertinib in previously treated advanced HER2-mutant non-small cell lung cancer: A single-center study.

  Jerry Kong, Richard Ni, Ainsley McCormack, Joshua K. Sabari
• E20544
  Non–small cell lung cancer and the obesity paradox: A retrospective cohort study using the TriNetX database.

  Areeba Nayyer, Chadane Thompson, Jasneet Gill, Shalva Eliava
• E20676
  Tumor histone H3 lysine 18 lactylation for the prediction of immunotherapy efficacy in patients with advanced non–small cell lung cancer.

  Zhe Wang, Haijun Zhang
• 8548
  Effect of gut microbiota–derived testosterone on distant metastasis in non–small cell lung cancer.

  Chen-Guang Liu, Dan Zang, Man Sun, Jun Chen
• E20060
  Immune-related adverse events and patient outcomes in non–small cell lung cancer: A silver lining?

  Susanna DSilva, Mu-Hsun Chen, Hong Zhu, Varinder Kaur
• 8653
  Molecular and immune profiling of BRAF -mutated ( BRAF MUT ) non-small cell lung cancer (NSCLC).

  Roupen Odabashian, Shuai Wang, Nishant Gandhi, Biagio Ricciuti et al.
• 11054
  Comprehensive molecular profiling in advanced non–small cell lung cancer (NSCLC): Measurable survival and value impacts of implementation.

  Stanley Ifeanyi Ozogbo, Tejaswi Gadela, Asmi Chattaraj, Srinishant Rajarajan et al.
• E20723
  Osimertinib in the treatment of EGFR mutation–positive advanced non-small cell lung cancer: A meta-analysis.

  Muhammad Hassan Raza, Jawaria Firdous, Madho Mal, Julia Grandinetti et al.
• TPS8668
  A phase 2/3 study of EIK1001 in combination with pembrolizumab and chemotherapy in participants with stage 4 non–small cell lung cancer (NSCLC) (TeLuRide-008).

  Dan Costin, Maria Gonzalez-Cao, Marissa Danielle Rybstein, Robert M. Jotte et al.
• E24026
  A meta-analysis and systematic review of cardiac adverse events in patients with HER2-altered non–small cell lung cancer (NSCLC) enrolled in clinical trials.

  Gabriel Cavalcante Lima Chagas, Amanda Ribeiro Rangel, Bruno Lins de Souza, Mary Pat Harnegie et al.
• E20666
  Impact of prior chemotherapy (CT) on dabrafenib plus trametinib (D + T) outcomes in BRAF V600E –mutated metastatic non–small cell lung cancer (NSCLC): A post hoc analysis.

  Jianya Zhou, Yan Lei, Manar Aoun, Su Miin Ong et al.
• E20556
  Spatial localization of epithelial-mesenchymal transition and immune niches in non-small cell lung cancer via interpretable gene set activity analysis.

  Andrew J. Yang, Chichun Tan, Ying Ma
• E20680
  Cigarette smoking on outcomes with osimertinib in EGFR -mutated non–small cell lung cancer: A real-world analysis.

  Mohammad Alamgir, Muhammad Yousaf, Jennifer Collins, Amir Kamran
• E20636
  Real-world outcomes of prolonged versus shorter duration pembrolizumab following chemoradiation in non–small cell lung cancer: A propensity-matched analysis.

  Anna Homeniuk, Anas Atrash, Ameera Syed
• E20624
  Development of a shared neoantigen peptide library to promote personalized vaccine strategy in patients with non–small cell lung cancer.

  Fangjun Chen, Shu Su, Mingyuan Xu, Lifeng Wang
• E20594
  PD-L1 score: Tool effectiveness in non-small cell lung cancer.

  Alexis Bennett, Sarah Sulkowski, Lily Zekavat, Aleksandra Karaseva et al.
• E20512
  Prospective evaluation of the pan-immune-inflammation value (PIV) as an independent prognostic biomarker in EGFR-mutated advanced non-small cell lung cancer.

  Deepa Aggarwal, Kadabur Nagendrappa Lokesh
• E20692
  Next-generation sequencing in non-small cell lung cancer management in Lebanon: Clinical practices and barriers to implementation.

  Mahmoud Hammad, Hasan Numan, Arafat H. Tfayli, Malek M. Safa
• 8582
  Impact of genomic HLA class I allelic imbalance on enduring immunotherapy response in advanced non–small cell lung cancer.

  Yiting Dong, Zhijie Wang, Jie Wang
• E23142
  Project IOTA (input optimization for tissue-based assays): Improving turnaround time (TAT) of mutation profiling for non-small cell lung cancer (NSCLC).

  Tripti Jain, Han Yu, Sean Glenn, Michael Petroziello et al.
• E20081
  Assessing adoption of neoadjuvant therapy in early-stage resectable non–small cell lung cancer: A retrospective review.

  Alisha Paro Maity, Stephanie Kjelstrom, Deric C. Savior, Arezoo Ghaneie et al.
• E20762
  Healthcare costs following osimertinib versus earlier-generation tyrosine kinase inhibitor initiation in non–small cell lung cancer: A U.S. claims-based study.

  Mohammad Alnuman, Ibrahim Warsi, Jyotirmoy Sarker, Kibum Kim
• E20024
  Spatial pathology–driven graph neural network modeling for predicting response to neoadjuvant immunotherapy in non–small cell lung cancer.

  Canjia Cai, Shaowei Wu, LuYu Huang, Guoqing Liao et al.
• 8067
  Survival outcomes of young patients with non-small cell lung cancer in Latin America: A real-world cohort study.

  Cristina Torres-Mallma, Ronald Hernan Calle Valdez, Luis Mas
• E20626
  First-line treatment patterns of advanced non–small cell lung cancer in patients with and without pre-existing autoimmune diseases.

  Alexi Archambault, Alexander Breskin, Claudia Shrefler, Sabina Sandigursky et al.
• 11071
  Concordance of tissue and plasma NGS in early-stage non–small cell lung cancer.

  Juhi Gor, Teri Hill, Mary M. Pasquinelli, Ryan Huu-Tuan Nguyen et al.
• E20686
  The landscape of MET alterations in non-small cell lung cancer in Southeast China: A real-world study.

  Sisi Zheng, Rixu Lin, Xiaoxiao Zhang, Ziyi Zuo et al.
• E20683
  A retrospective analysis examining liquid biopsies with tissue biopsies in patients with advanced non–small cell lung cancer.

  Alix Taylor Rosenberg, Rebecca Ehrenkranz, Codruta Chiuzan, Pratik Shah et al.
• E20689
  Real-world outcomes of crizotinib treatment for ALK+ and ROS1+ metastatic non-small cell lung cancer in Nepal.

  Arun Shahi, Bipin Poudel, Alicia Annamalay, Manoj Menon et al.
• E20675
  Obese patients with non-small cell lung carcinoma and the intratumor microbiome and immune microenvironment.

  Haroon Ali, Bingqing XIe, Jun Yang, Urooba Nadeem
• E23419
  Arterial and venous thromboembolic events in ALK - and ROS1 -positive non–small cell lung cancer (NSCLC): A multicenter real-world analysis.

  Kim Abbegail Tan Aldecoa, Ibrahim Azar, Chef Stan Lucena Macaraeg, Cathleen Park et al.
• TPS8660
  SigVie-003: Phase 3 trial of frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab alone in non-small cell lung cancer (NSCLC) with PD-L1 TPS ≥50%.

  Martin Reck, Shun Lu, Kenneth John O'Byrne, Carlos H. Barrios et al.
• E20069
  Comparative analysis of neoadjuvant chemoimmunotherapy (chemoIO) versus PD-(L)1 monotherapy (mono) across PD-L1 expression strata in resectable non–small cell lung cancer (NSCLC): A systematic review and meta-analysis of prospective trials.

  Chad Sussman, Cathy Zhang, Zhichen Xiong, Patrick M. Forde et al.
• 8539
  A real-world analysis of ctDNA methylation-based histology prediction and associated clinical characteristics in non–small cell lung cancer (NSCLC).

  Jessica Zhang, Samer Yassin, Jack Shapiro, Dilsa Mizrak Kaya et al.
• TPS8662
  Petosemtamab plus pembrolizumab as first-line (1L) treatment of PD-L1 high metastatic non-small cell lung cancer (NSCLC): Global phase 2 trial.

  Paul K. Paik, Koichi Goto, Alexander I. Spira, Wade Thomas Iams et al.
• E20058
  Retrospective study on safety and efficacy of hypofractionated versus conventional fractionated sequential radiotherapy for stage III unresectable non-small cell lung cancer.

  Xixi Zhao, Shupei Pan, Ruijuan Zhang, Shangyi Geng et al.
• 8054
  Response to neoadjuvant chemoimmunotherapy in EGFR- or ALK-mutated non-small cell lung cancer.

  Giorgio Caturegli, Ebony Jernigan, Maureen Canavan, Abigail Lynch et al.
• E20097
  Real-world outcomes and immune and cardiopulmonary toxicities of durvalumab following concurrent chemoradiotherapy in non–small cell lung cancer.

  Shuai Wang, Kith Pradhan, Nitin Ohri, Ethan Pan et al.
• E20696
  Once unthinkable: Population-level changes in five-year survival for metastatic non–small cell lung cancer in the immunotherapy era.

  Ujwala Koduru, Maxwell Oluwole Akanbi, Jerry Kenmoe, Shiva Shrotriya et al.
• E20100
  Risk of venous thromboembolism in resectable non-small cell lung cancer treated with neoadjuvant and adjuvant immunotherapy: A self-controlled case series.

  Jessie Li, Ryan Huu-Tuan Nguyen, Marwah Wafa Farooqui
• 11184
  Baseline corticosteroid use and outcomes in non–small cell lung cancer patients receiving immune checkpoint inhibitors, stratified by indication.

  Angelina Lim, Kenneth Nguyen, Fumito Ito, Jorge J. Nieva et al.
• E20705
  Real-world outcomes in EGFR subtypes and co- TP53 mutations in metastatic non-small cell lung cancer.

  Nina Cheranda, Neha Puttagunta, Divya Chukkalore, Wint Yan Aung et al.
• E20045
  Endothelin-1 levels in lung tissue of patients with non–small cell lung cancer with previous COVID-19 of varying severity.

  Ekaterina I. Surikova, Elena M. Frantsiyants, Valeria Bandovkina, Galina V. Zhukova et al.
• E24075
  Association between tumor mutation status, pretreatment weight change, and overall survival in metastatic non–small cell lung cancer.

  Ye Myint Aung, Aynur Aktas, Kunal C. Kadakia, Robert Clevenger et al.
• 8547
  Genomic characterization of SMARCA4 -mutant versus wild-type non–small cell lung cancer in a Chinese population: A large-scale next-generation sequencing study.

  Tongguo Si, Mao Yang, Yongfei Guo
• E20056
  Targeted bronchial washing fluid–based sequencing for detection of actionable genomic alterations in early-stage non–small cell lung cancer: A comparative analysis with plasma and surgical tissue.

  Jung seop Eom, Soohan KIM
• E20582
  Deep learning–based imaging models for predicting immune checkpoint inhibitor response in non–small cell lung cancer: A systematic review.

  Kunhee Kim, Sunwoo Lee, Yujin Lim, Jaehyun Park et al.
• E20750
  Comparison of DNA+RNA co-detection and DNA-only NGS for driver gene identification and co-mutation profiling in Chinese patients with non–small cell lung cancer.

  Xisheng Fang, Yonghao Li, Jiejian Chen
• 8650
  Comprehensive profiling of EGFR PACC mutations and their co-mutation landscape in Chinese patients with non–small cell lung cancer: A large-scale NGS study of 2,360 cases.

  Yuan Jiang, Mingyue Lin
• E20717
  Real-world outcomes of amivantamab monotherapy in advanced EGFR-mutant non-small cell lung cancer.

  Siddarth Ganesh, Lili Zhang, Ayrton Bangolo, Sarvarinder Kaur Gill et al.
• E20685
  Age-vulnerability interaction and real-world treatment outcomes in EGFR -mutant non–small cell lung cancer.

  Juliet Meir, Divya Chukkalore, Wint Yan Aung, Nehemias Guevara et al.
• E20740
  Lorlatinib as first-line therapy for ALK-positive advanced non-small cell lung cancer: A retrospective, multicenter, real-world study from China.

  Jianya Zhou, Pei Zhang, Jing Zheng, Yuping Li et al.
• 8630
  Hi-C sequencing to identify clinically actionable fusions in non–small cell lung cancer missed by other sequencing technologies.

  Kevin Max Levine, Alex Hastie, Anthony Schmitt, Siddarth Selvaraj et al.
• E13735
  Rural-urban survival differences in advanced non–small cell lung cancer in the modern treatment era: A SEER-based analysis.

  Adit Dharia, Sukriti Seth, Ayse Gul Korkmaz, Supriya Peshin et al.
• E20703
  Predictors of mortality in hospitalized patients with metastatic non-small cell lung cancer (mNSCLC) with or without idiopathic pulmonary fibrosis (IPF).

  Louisa Aniekeme Etuk, Ayobami Gbenga Olafimihan, Olanipekun Lanny Ntukidem, Selena Khanna et al.
• 8566
  Effect of dual immune checkpoint inhibitors (ICI) by the time of infusion in advanced non–small cell lung cancer (NSCLC): A secondary analysis of CCTG BR34 trial.

  Sze Wah Samuel Chan, Adi Kartolo, Keyue Ding, Pierre-Olivier Gaudreau et al.
• 8550
  Impact of KRAS co-mutations on the efficacy of durvalumab in patients with locally advanced non–small cell lung cancer (LA-NSCLC) treated with concurrent chemoradiotherapy (ChRT).

  Jaime Rubio Perez, Ling Feng Ye, Matteo Repetto, Sameh Nabeeh Daher et al.
• E20073
  Adebrelimab in combination with anlotinib and chemotherapy as neoadjuvant therapy for resectable stage II-III non–small cell lung cancer (NSCLC): A prospective, single-arm, phase II trial.

  Meng Wang, Yu Zhang, Bin Jia, Changli Wang et al.
• TPS8130
  Randomized, double-blind, phase 3 TRUST-IV study of adjuvant taletrectinib vs placebo in patients with stage IB–IIIA ROS1+ non-small cell lung cancer (NSCLC).

  Alexander I. Spira, Alexander E. Drilon, Jonathan W. Goldman, Narjust Florez et al.
• E14515
  Engineering and preclinical evaluation of CXCR3-expressing, EGFR-targeted CAR-NK cells for tumor homing in non–small cell lung cancer and esophageal squamous cell carcinoma models.

  Lijuan Shao, Size Chen, Xiaofei Cao, Canfeng He et al.
• TPS8661
  AndroMETa-Lung-713: A phase 2/3 study of telisotuzumab adizutecan (ABBV-400, Temab-A) vs standard of care (SOC) in patients with epidermal growth factor receptor ( EGFR )–mutated non–small cell lung cancer (NSCLC).

  Adam Rock, Yi-Long Wu, Se-Hoon Lee, Enriqueta Felip et al.
• TPS8669
  Lung-MAP S1800E: A randomized phase II/III study of docetaxel and ramucirumab with or without cemiplimab for patients previously treated with platinum-based chemotherapy and immunotherapy for stage IV or recurrent non-small cell lung cancer (NSCLC).

  Saiama Naheed Waqar, Mary Weber Redman, Tianhong Li, Katherine Minichiello et al.
• E20569
  Survival outcomes of PD1/PDL1 inhibitor-based regimens in unresectable stage IIIB, IIIC, and IV non-small cell lung cancer.

  Barath Prashanth Sivasubramanian, Chiugo Okoye, Palwasha Khan, Shikha Upreti et al.
• E20768
  Association of caregiver and patient burden with ALK-positive advanced non–small cell lung cancer in Germany, the United Kingdom, and the United States.

  Hoa Le, Hollie Bailey, Helen Burlison, Tom Brown et al.
• E24068
  Thromboembolic events in patients with advanced non-small cell lung cancer receiving palliative chemoimmunotherapy with pembrolizumab.

  Tae-Hwan Kim, Cheongin Yang, Yong Won Choi, Mi Sun Ahn et al.
• E13794
  A feasibility and usability study of a virtual exercise platform in patients with non–small cell lung cancer in a large academic center.

  Shuyi Chen, Melissa Francoise Neumann, Tracy Green, Meredith Akerman et al.
• E22525
  Real-time breath volatile organic compound analysis for detection of newly diagnosed, treatment naïve non-small cell lung cancer: A pilot study.

  Prabhpreet Kaur, Kumaran Kavyadharshini, Jason Ng, Fuchang Zhang et al.
• 8102
  Impact of lung cancer screening in patients diagnosed with small cell lung cancer.

  Paresh Kumar, Emmalee E. Kiser, Brook Marie Lobsiger, Anthony Alfonso et al.
• E24076
  Palliative care utilization in patients with EGFR -mutant metastatic non-small cell lung cancer receiving first-line EGFR TKIs.

  Divya Chukkalore, Wint Yan Aung, Nina Cheranda, Neha Puttagunta et al.
• E20541
  Drivers of organotropism and patterns of metastatic progression in metastatic non–small cell lung cancer.

  Gabriela Esnaola, Benjamin Resio, Alexander Pan, Daniel Lee et al.
• E20642
  Real-world outcomes of immune checkpoint inhibitors in patients aged 65–74 versus ≥75 years with non-small cell lung cancer.

  Sameeha Sajid, Muhammad Daud Abdullah, Daniel Thomas Jones, Rakahn Haddadin et al.
• 8061
  Characteristics of patients with resectable early-stage non–small cell lung cancer treated with neoadjuvant chemoimmunotherapy or surgery ± adjuvant therapy.

  Pragya Rai, Yu-Han Kao, Ashwini Arunachalam, Jeffrey Thompson et al.
• 12155
  Cardiovascular toxicity across epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in EGFR -mutated non–small cell lung cancer: A population-based retrospective cohort study.

  Yun-Gyoo Lee, Dayeon Seo, Jungwon Choi
• E20715
  Aumolertinib as first-line therapy for locally advanced or metastatic EGFR -mutant non–small cell lung cancer: A single-arm meta-analysis.

  Fatima Ali, Ahmed M. Kedwany, Athar Nawab, Amna Khalid et al.
• E20047
  The influence of COVID-19 severity on the local lung hormonal profile in patients with non-small cell lung cancer.

  Ekaterina I. Surikova, Elena M. Frantsiyants, Valeria Bandovkina, Irina Valerevna Neskubina et al.
• 8621
  Cost-effectiveness of amivantamab plus lazertinib versus osimertinib plus chemotherapy for first-line treatment of EGFR ‐mutated advanced non–small cell lung cancer.

  Pooja Gokhale, Joshua Caballero, Niying Li, Lorenzo A. Villa Zapata
• E20084
  Surgical outcomes of sleeve versus standard lobectomy in patients with non–small cell lung cancer: A systematic review and meta-analysis.

  Marcílio De Oliveira Filho, Jean Henri Maselli-Schoueri, Mariana Macambira Noronha, Basant Mahmoud et al.
• 8545
  AI-powered characterization of the tumor microenvironment landscape in HER2-overexpressing non–small cell lung cancer.

  Woochan Hwang, Seungeun Lee, Chang Ho Ahn, Sanghoon Song et al.
• 8062
  Impact of adjuvant immunotherapy after pathologic complete response to neoadjuvant chemo-immunotherapy in resected stage II–III non–small cell lung cancer.

  Joseph Zouein, Brady Kupersmith, John Aversa, Kinjal Dargan et al.
• E20617
  Impact of poor performance status on outcomes with immune checkpoint inhibitors in advanced non–small cell lung cancer: A systematic review and meta-analysis.

  Disha Patel, Parjanya Shah, Nikhila Chelikam, Siddharth Gandhi et al.
• LBA8507
  A randomized, open-label, parallel-controlled phase 3 trial of benmelstobart plus chemotherapy and anlotinib for first-line treatment of advanced non-squamous non–small cell lung cancer.

  Yuankai Shi, Xiaoyong Tang, Lin Wu, Wei Guo et al.
• E15059
  Dynamic remodeling of the extracellular vesicle proteome during systemic therapy in advanced non–small cell lung cancer.

  Anna Paola Carreca, Antonio Galvano, Valerio Gristina, Lorena Incorvaia et al.
• E20588
  Effects of upfront dual immunotherapy on overall survival in patients with metastatic non-small cell lung cancer with no targetable mutations or PD-L1 expression.

  Esteban Toro Velez, Carolina Velez-Mejia, Andrew Stewart Poklepovic, Renato G. Martins
• E20599
  The significance of MDM-2 positivity in stage 4 non-small cell lung cancer.

  Oguz Kara, Şuheda ataş Ipek, Fatma çalkan Gündüz, Derya Gumurdulu et al.
• E20020
  Prediction of postoperative recurrence in non–small cell lung cancer using machine learning approaches.

  Uğur Özberk, Seli̇n Aktürk Esen, Hilal Arslan, Oznur Bal et al.
• E20578
  Clinical outcomes among patients with metastatic non–small cell lung cancer (mNSCLC) who received immune checkpoint inhibitors (ICI) in first (1L) and second line (2L).

  Terra Wonsettler, Adie Fridman, Aliza R. Karpes-Matusevich, Kathryn Penney et al.
• 10557
  Use of multiplex digital profiling of DNA methylation heterogeneity to enable sensitive early detection of non–small cell lung cancer from low-volume liquid biopsies.

  Christine O'Hersey, Yang Zhao, Thomas Pisanic, James Herman et al.
• E20771
  Epidemiologic and clinicopathological characteristics of SMARCA4-deficient non–small cell lung cancer form a single center in Yunnan, China.

  Miao Wang, Bo Yang, Haoyu Li, Chaozhen Shang et al.
• E20649
  Utilization patterns and disparities in supportive oncology services for patients with stage IV non-small cell lung cancer.

  Rebekah S. Feld, Luxiga Thanabalachandran, Daniel Jafari, Wilma M. Hopman et al.
• E20765
  Intracranial efficacy of osimertinib in EGFR -mutated non–small cell lung cancer with brain metastases: A meta-analysis.

  Namita Ruhela, Khalid Ahmad Qidwai, Ruchit Jain, Zouina Sarfraz et al.
• 2571
  Exploratory biomarker analysis of ociperlimab (OCI) plus tislelizumab (TIS) in patients (pts) with PD-L1–positive non–small cell lung cancer (NSCLC) in AdvanTIG-105.

  Yan Yu, Yanyan Peng, Wei Tan, Guohua Yu et al.
• 8629
  Patient-reported outcomes (PROs) and health-related quality of life (HRQoL) with taletrectinib in advanced ROS1+ non-small cell lung cancer (NSCLC) from the TRUST-II study.

  Yasir Y. Elamin, Scott Peter Owen, Lyudmila Bazhenova, Maurice Perol et al.
• TPS2678
  A phase 1b, two-arm study of tolododekin alfa (ANK-101) in combination with an anti–PD-1/PD-L1 antibody in participants with advanced non–small cell lung cancer (NSCLC).

  Thomas Urban Marron, Michael A. Pritchett, Nikhil Shukla, Tarik Hadid et al.
• TPS8680
  A phase II study of amivantamab hyaluronidase in MET amplification–positive stage IV or recurrent non–small cell lung cancer (Lung-MAP Sub-Study).

  Christian Diego Rolfo, Mary Weber Redman, Shirish M. Gadgeel, Katherine Minichiello et al.
• 12059
  Negative effect of malignant pleural effusion on the efficacy of immunotherapy via IL-6–mediated abscopal immunosuppression in advanced non-small cell lung cancer.

  Yaping Guan, Yuekai Zhang, Yue Dong, Jiang Chang et al.
• E20091
  Real-world clinical impact and prognostic utility of circulating tumor DNA in stage I–IV non–small cell lung cancer.

  Fernando Poli, Andrea Poli de Frias, Eric Spinetti, Cedric Christophe Nasnas et al.
• 8587
  Immunonutrition intervention in driver gene–negative non–small cell lung cancer patients with sarcopenia: A randomized controlled trial.

  Xiangliang Liu, Jin Lu, Wei Song, Huimin Tian et al.
• 8056
  Prediction of survival outcome in clinical stage II-III non-small cell lung cancer undergoing neoadjuvant chemoimmunotherapy: Role of ypN status vs PCR.

  Hannah Hoang, Jorge Raul Vazquez-Urrutia, Junjia Zhu, Shinkichi Takamori et al.
• E20041
  Sequencing strategy of immunotherapy with chemoradiotherapy in stage III non–small cell lung cancer: A pooled analysis of prospective trials.

  Yue Li, Junmin Song, Xin-yun Song, Xiaoyi Zhang et al.
• 11138
  A risk stratification schema for patients with non–small cell lung cancer with multiple organ metastases.

  Gabriela Esnaola, Mengru Wang, Benjamin Resio, Alexander Pan et al.
• E20072
  Real-world utilization and survival trends of adjuvant immunotherapy in postoperative stage II-III non-small cell lung cancer: A Louisiana population-based study.

  Yen-Han Tseng, Yen-Chiang Tseng, Yi-Hsuan Lin, Yuh-Min Chen et al.
• 11116
  Factors associated with clinical trial failure and termination in non–small cell lung cancer immunotherapy: A ten-year review.

  Arman Asatryan, Amalya Sargsyan, Shushan Hovsepyan, Meri Ghayamyan et al.
• E20538
  Association of RNA-based immune gene expression with immunotherapy duration in advanced non–small cell lung cancer.

  Jerrin Joy Pullukkara, Zarifa Gahramanli Ozturk, Aileen Y. Alontaga, Junmin Whiting et al.
• E23377
  Real-world utilization of upfront genomic testing in newly diagnosed non–small cell lung cancer in a rural state.

  Kimberly J. Toomire, Jeanne Wishengrad, Nicole Hudak, Eric Anderson et al.
• E20000
  The use of multimodal machine learning models for predicting overall survival in patients with non-small cell lung cancer: A systematic review.

  Cristian Soto Jacome, Andrea Arce-Camposano, David Silva Segovia, Eddy P. Lincango Naranjo et al.
• E20560
  Association of early on-treatment cytokine dynamics following induction chemo-immunotherapy with progression-free survival in squamous non–small cell lung cancer.

  Amrita Roy, Jonathan Q. Trinh, Dikshaya Prabhakara, Apurva Mallisetty et al.
• TPS8678
  First-in-human phase I, open-label, multicenter study of HJ-004, a novel EGFR-PROTAC degrader, in patients with advanced EGFR -mutated non–small cell lung cancer.

  Xinru Chen, Caicun Zhou, Li Zeng, Ya Geng et al.
• E20109
  Real-world treatment patterns and toxicity of durvalumab after chemoradiation in stage III non-small cell lung cancer.

  Malu Viter Da Rosa Barbosa, Khloe Campos, Tatianny Paula Araujo Vargas, Julia Belone Lopes et al.
• E20122
  Tumor mutational burden by smoking status in small cell lung cancer: Insights from a limited cohort.

  Thomas Greco, Tahreem Malik, Joseph Maslak
• E20129
  Stage-specific survival trends in small cell lung cancer in the United States: A population-based analysis.

  Michael Barsoum, Bushra A. Mina
• E20165
  Clinicogenomic characterization of MUC16 and MUC17 in small cell lung cancer.

  Nina Cheranda, Neha Puttagunta, Divya Chukkalore, Wint Yan Aung et al.
• E20162
  Investigating transcriptional regulation of cisplatin sensitivity in small cell lung cancer using a functional overexpression screen.

  Andrea Penrose, Michael Gottesman, Allison Mitchell
• 8112
  Predictive role of immune cell subsets and intestinal flora in immune-related adverse event of small cell lung cancer.

  Mei-xi Lin, Man Sun, Dan Zang, Jun Chen
• E20748
  A multicenter pilot study of afatinib re-challenge in patients with EGFR -mutated non-squamous non–small cell lung cancer previously treated with osimertinib.

  Taisuke Araki, Ryo Ichikawa, Akane Kato, Manabu Yamamoto et al.
• E20038
  Stereotactic body radiotherapy versus non-SBRT radiotherapy for medically inoperable stage I non–small cell lung cancer in elderly patients: A systematic review and meta-analysis.

  Fnu Sawaira, Aizaz Anwar Khalid, Owais Gul, Muhammad Waqas et al.
• 8034
  Outcomes of atypical EGFR mutations in early-stage EGFR -mutated non-small cell lung cancer (NSCLC).

  Jacqueline V. Aredo, Surbhi Singhal, Mandeep Banwait, Emily Guo et al.
• E20607
  Characterization of tumor immune microenvironment and real-world efficacy of first-line immunotherapy in BRAF -mutant non–small cell lung cancer.

  Yang Cao, Wei Wang, Lin Yang, Weihua Li et al.
• E20565
  EGFR mutational landscape in non–small cell lung cancer: A 10-year experience of a national reference laboratory in Colombia (2014–2023).

  Carolina Lopez Ordoñez, Ruby Rios, Ivan Bravo, Duneida Ramos et al.
• 8652
  Circulating tumor DNA dynamics following molecularly targeted therapy for non–small cell lung cancer.

  Justin Jee, Avinash Ramu, Diego Almanza, Sumedha Sudhaman et al.
• E14579
  Precision or perplexity: Assessment of discordance among different PD-L1 assays in the same specimen in advanced non–small cell lung cancer in a community setting.

  Hamza Usman, Salman J. Khan, Madhuri Yalamanchili, Seemab Sheikh et al.
• E20700
  Efficacy and safety of intrathecal chemotherapy in EGFR -mutant non–small cell lung cancer with leptomeningeal metastases: A systematic review and meta-analysis.

  Rishi Kumar Nanda, Daniel Thomas Jones, Kyaw Zin Thein, Ashley Potter et al.
• E20543
  Role of ATM as a prognostic biomarker in non small cell lung cancer: A systematic review and meta-analysis.

  Muhammad Junaid Iqbal, Amina Hassan, Fatima Aslam, Hamza Tanveer et al.
• E20753
  Comparative effectiveness of ALK tyrosine kinase inhibitors in ALK-positive non–small cell lung cancer: A systematic review and network meta-analysis.

  Yashasvi Srivastava, Shankar Biswas, Elangovan Krishnan, Rahul Falodia et al.
• 2559
  Optimization of tumor-infiltrating lymphocyte (TIL) manufacturing in non-small cell lung cancer (NSCLC) using an IL-7/IL-15/IL-2 expansion protocol.

  Jorge Bartolome, Daniel Tovar, María Mateos González, Nabil Subhi-issa et al.
• E20595
  Effect of immune checkpoint inhibitor infusion timing on overall survival in non–small cell lung cancer: A real-world retrospective study.

  Nency Ganatra, Ahmed Abdelhakeem, Pragya Jain, Jinish Doshi et al.
• E20529
  Role of circulating miR-30a-5p and miR-93-5p as liquid biopsy biomarkers for prediction of prognosis in metastatic non-small cell lung cancer.

  Ashraf Hassan Helmy Elsayed, Ola Khorshid, Hala Aziz Shokralla Makar, Shaimaa Abdalgeleel et al.
• E20603
  Early vs late survival patterns of chemoimmunotherapy compared with immune checkpoint inhibitor monotherapy in non–small cell lung cancer.

  Ryo Ariyasu, Teruhisa Nemoto, Hirokazu Iso, Masahiro Ito et al.
• 2026
  Cerebrospinal fluid biomarker profiling in patients with non–small cell lung cancer and leptomeningeal disease.

  Mark Yungjie Jeng, Jessica Wilcox, Samuel Tischfield, Anne S. Reiner et al.
• 11187
  Impact of diabetes on respiratory infection risk and hospitalization following immune checkpoint inhibitor initiation in non–small cell lung cancer: A propensity-matched retrospective cohort analysis.

  Gurasis Singh Sodhi, Dhriti Sood, Vishan Ramanathan, Esteban Kosak Lopez et al.
• 8033
  Class-specific clinical and molecular features of SMARCA4 alterations in non–small cell lung cancer.

  Chihiro Takemura, Tatsuya Yoshida, Kouya Shiraishi, Yukihiro Yoshida et al.
• E20641
  Impact of age on immune-related toxicities and survival in non–small cell lung cancer treated with immune checkpoint inhibitors: A multicenter retrospective study.

  Shruti Shah, Deevyashali Parekh, Safa Saadat Afridi, Ansy Patel et al.
• E23309
  Advancing HER2 testing and evidence-based treatment in non–small cell lung cancer: A quality improvement initiative across academic and community settings.

  Kelly E. McKinnon, Benjamin Philip Levy, Osman Yilmaz, Rewatee Gokhale et al.
• E20746
  Impact of first-line EGFR TKI dose reduction on survival and treatment sequencing in metastatic EGFR -mutant non–small cell lung cancer: A real-world cohort study.

  Divya Chukkalore, Wint Yan Aung, Nina Cheranda, Neha Puttagunta et al.
• E20602
  Systemic antibiotic exposure and outcomes of immune checkpoint inhibitors in non–small cell lung cancer.

  Giuliana Ciappina, Enrica Toscano, Patrizia Carroccio, Giordana Di Mauro et al.
• 8552
  Clinico-genomic landscape and prognostic impact of APC/CTNNB1 oncogenic alterations in non–small cell lung cancer.

  Leonardo Brunetti, Valentina Santo, Eleonora Gariazzo, Cassio Murilo Hidalgo-Filho et al.
• 1522
  Association of socioeconomic and clinical factors with overall survival in immunotherapy-eligible stage III non-small cell lung cancer following definitive chemoradiation.

  Chaewon Hwang, Jincong Q. Freeman, Daniela Reyes, Hannah Koo et al.
• E20660
  Early versus delayed initiation of first-line immune checkpoint inhibitors in metastatic non–small cell lung cancer: A real-world analysis of treatment timing and care context.

  Nandhini Iyer, Ansy Patel, Deevyashali Parekh, Avi Ravi Harisingani et al.
• E20772
  Efficacy and safety of HER2-targeted tyrosine kinase inhibitors in HER2 -mutant non–small cell lung cancer: A systematic review and meta-analysis.

  Harshawardhan Ramteke, Haroon Alamy, Rabeeh Ummer, Ahmed Shafeeg et al.
• E20633
  Real-world outcomes of first-line treatments in patients with metastatic non-small cell lung cancer: Final analysis of the Registurk-Lung registry.

  Sema Sezgin Goksu, Mehmet Artac, Ahmet Sezer, Abdurrahman Isikdogan et al.
• E20127
  Real-world efficacy and safety of tarlatamab in small cell lung cancer (SCLC) and extrapulmonary small cell carcinoma (EPSCC): A single-center experience.

  Ayrton Bangolo, Lili Zhang, Sarvarinder Gill, Shibhani Rajanna et al.
• E20145
  Impact of inulin on immunotherapy efficacy in extensive-stage small cell lung cancer and on promotion of CD8+ T-cell tumor infiltration and functional activity.

  Qiangguo Sun, Dan Zang, Jun Chen
• E20168
  Real-world survival and safety outcomes of tarlatamab in patients with extensive stage small cell lung cancer.

  Sangam Sangam, Sneha Singh, Anuja Vidyadhar Abhyankar
• 8069
  Age-based differences in outcomes among small cell lung cancer patients treated with tarlatamab.

  Raymart Macasaet, Vinit Singh, Grace K. Dy, Doantrang Du
• E23393
  Real-world outcomes of atezolizumab versus durvalumab in extensive-stage small cell lung cancer.

  Elsy Rivera, Kevin Zhu, Haley Moriarty, Margaux Eller et al.
• E20163
  Outcome of chemotherapy among intubated patients with small cell lung cancer: A systematic review.

  Ayush Adhikari, Tibbin Shiwakoti, Pravash Budhathoki, Egesh Aryal et al.
• 8588
  Efficacy outcomes in first-line (1L) non–small cell lung cancer (NSCLC) with maintenance of immune competence: QUILT-2.023 randomized phase 3 study of IL-15R agonist nogapendekin alfa inbakicept (NAI) with checkpoint inhibitor (CPI) ± chemotherapy.

  John M. Wrangle, Luke P. Dreisbach, Amol Rajeev Rao, Chaitali Singh Nangia et al.
• E20046
  Dysregulation of the insulin-like growth factor system in non–small cell lung cancer tissue and histologically normal lung tissue in patients with varying degrees of COVID-19 severity.

  Dmitry A. Kharagezov, Elena M. Frantsiyants, Valeria Bandovkina, Ekaterina I. Surikova et al.
• 8594
  A phase 2 study of docetaxel (D), ramucirumab (R), and pembrolizumab (P) for patients with metastatic or recurrent non–small cell lung cancer (NSCLC) who progressed on platinum-doublet and PD-1/PD-L1 blockade.

  Badi Edmond El Osta, Jennifer W. Carlisle, Conor Ernst Steuer, Manali Rupji et al.
• E13542
  Deconstructing implementation of reflex biomarker testing in non–small cell lung cancer (NSCLC): Diverse strategies to overcome barriers.

  Julia R. Trosman, Christine B. Weldon, Mary Beth Beasley, Ryan Huu-Tuan Nguyen et al.
• E20106
  Perioperative outcomes and early survival after curative-intent non–small cell lung cancer (NSCLC) resection in a Colombian tertiary center.

  Juliana Pardo, Mateo Barros, Maria Paula Uchima-Vera, Manuela Estrada et al.
• 8586
  IBI363 (TAK-928) plus chemotherapy as first-line (1L) treatment for advanced non–small cell lung cancer (NSCLC).

  HaiYan Tu, Yong Wang, Hongxu Liu, Dingzhi Huang et al.
• 8597
  Early lipid-lowering therapy initiation after lorlatinib and clinical outcomes in non–small cell lung cancer: A propensity-matched real-world analysis.

  Sooraj Srirangadhamu Gopu, Siddharth Pravin Agrawal, Kanishka Uttam Chandani, Jatin Thukral et al.
• E20563
  Concordance of EGFR and KRAS mutation status between primary non–small cell lung cancer and corresponding metastases: A systematic review and meta-analysis.

  Rahul Falodia, Shankar Biswas, Elangovan Krishnan, Yashasvi Srivastava et al.
• 2627
  Low-dose intestinal irradiation to enhance the efficacy and prognosis of PD-1 blockade in metastatic non-small cell lung cancer.

  Baiyang Huang, Jiarui Zhao, Jingyu Zhu, Xingpeng Wang et al.
• E20031
  Real-world use and prognostic performance of a 14-gene molecular risk assay in stage IA–IIA non-small cell lung cancer.

  Andrea Poli de Frias, Fernando M. Safdie, Roy F. Williams, Fernando Poli et al.
• 8071
  Real-world impact of first immunotherapy infusion timing on outcomes in locally advanced non-small cell lung cancer.

  Mumtu Lalla, Puneet Dhillon, Brendon Fusco, Chenxin Zhang et al.
• E20612
  Impact of pre-existing autoimmune disease on outcomes of immune checkpoint inhibitors in non–small cell lung cancer: A real-world multi-institutional cohort study.

  Syed Abdul Mannan Shah, Nanda Krishnan Siva, Shanawar Ali Waris, Muqtasid Aftab Khan et al.
• E20079
  Osimertinib plus savolitinib in osimertinib-resistant non-small-cell lung cancer with low level gene copy number MET: A multi-center, open-label, and phase 2 study.

  Xiang Han, Zhongfa Zhang, Ling Zhang, Xiuhui Guo et al.